Northeast Financial Consultants Inc Ligand Pharmaceuticals Inc Transaction History

Northeast Financial Consultants Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	BUY	$94.99 - $151.56 $83,496 - $133,221	879 Added 46.86%	2,755 $309,000
Q2 2021 Aug 16, 2021	BUY	$113.03 - $155.64 $212,044 - $291,980	1,876 New	1,876 $246,000
Q3 2020 Oct 29, 2020	SELL	$89.56 - $126.72 $171,507 - $242,668	-1,915 Closed	0 $0
Q2 2020 Jul 30, 2020	BUY	$68.28 - $123.65 $130,756 - $236,789	1,915 New	1,915 $214,000
Q1 2020 May 13, 2020	SELL	$63.37 - $107.88 $121,353 - $206,590	-1,915 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$96.94 - $113.59 $185,640 - $217,524	1,915 New	1,915 $200,000
Q3 2019 Nov 13, 2019	SELL	$86.25 - $120.16 $165,168 - $230,106	-1,915 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$105.93 - $142.47 $202,855 - $272,830	1,915 New	1,915 $241,000

262

18M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.94B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Northeast Financial Consultants Inc, based on Form 13F filings with the SEC.

Stay updated on Northeast Financial Consultants Inc with notifications on news.